Synthomer (SYNT) H2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2025 earnings summary
8 May, 2026Executive summary
Delivered improved margins and robust trading performance in 2025 despite lower end-market demand and global tariff changes, with results in line with prior guidance and positive free cash flow.
Strategic focus on specialty products, cost savings, and portfolio simplification drove resilience and operational progress, supported by ongoing transformation towards specialty chemicals.
Refinanced bank facilities, extending maturities to 2029 and resetting covenants, ensuring financial stability.
Divestment program broadened, with four active processes and the divestment of William Blythe to accelerate deleveraging and focus on core specialty businesses.
Q1 2026 trading showed improving momentum, with robust volume and margin outlook for Q2 and potential upside risks for the year.
Financial highlights
Group revenue for continuing business down 9.9% year-over-year to GBP 1.74 billion; volume down 7.2%.
EBITDA reduced by 4.5% to GBP 137 million, but EBITDA margin expanded by 40 bps to 7.8% due to cost efficiencies; gross margin up 200 bps.
Underlying operating profit at GBP 37.6 million, down 21%; underlying loss per share worsened to GBP 0.372, mainly due to tax asset derecognition.
Net debt at GBP 575 million, GBP 22 million lower year-on-year; leverage at 4.7x, within covenant limits; positive free cash flow achieved.
GBP 30 million in operating cost savings achieved in 2025, with further GBP 20–25 million targeted for 2026.
Outlook and guidance
Expect robust improvement in volumes and margins in Q2 2026, with upside risks if current trading conditions persist.
Full-year 2026 guidance unchanged, with self-help actions and specialty focus expected to drive year-on-year progress.
Free cash flow for 2026 expected to be broadly neutral after adjusting for one-time receivables transaction.
Dividend remains suspended until leverage falls below 2.5x.
Wage inflation and bonus accrual normalization expected to partially offset gains.
Latest events from Synthomer
- 2025 guidance reaffirmed; refinancing and divestment progressing, with 2026 trading on track.SYNT
Trading update19 Mar 2026 - Revenue, EBITDA, and margins rose in H1 2024, with positive FCF outlook and ongoing transformation.SYNT
H1 20241 Feb 2026 - Margins improved and cash flow remained positive despite lower revenue in challenging markets.SYNT
Q4 2025 TU29 Jan 2026 - Strong 2024 growth, specialty focus, and positive 2025 outlook despite market headwinds.SYNT
H2 202417 Dec 2025 - EBITDA and margin gains offset revenue drop; cost cuts and deleveraging remain priorities.SYNT
H1 202523 Nov 2025 - Resilient Q3 2025 performance, stable EBITDA outlook, and ongoing cost-saving and transformation efforts.SYNT
Q3 2025 TU23 Oct 2025 - Q3 2024 delivered improved volumes and EBITDA, with strategic progress and positive cash flow outlook.SYNT
Trading Update13 Jun 2025 - Q1 2025 EBITDA and margins rose, driven by self-help and specialty growth initiatives.SYNT
Trading Update6 Jun 2025 - 2024 revenue and EBITDA met expectations, with strong margins and strategic progress.SYNT
Trading Update6 Jun 2025